CD40 Ligand (CD40L) Antibody Global Market Report 2025

The CD40 ligand (CD40L) antibody market size has grown rapidly in recent years. It will grow from $0.63 billion in 2024 to $0.7 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth during the historic period can be attributed to the increasing prevalence of autoimmune diseases, the rising demand for targeted cancer treatments, expanding research on immune modulation, regulatory approvals for novel biologics, growing healthcare expenditures, and the increasing adoption of personalized medicine approaches.

The CD40 ligand (CD40L) antibody market size is expected to see rapid growth in the next few years. It will grow to $1.03 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth during the forecast period can be attributed to the rising adoption of personalized medicine, increasing research investments in autoimmune and transplant therapies, growing regulatory approvals for novel treatments, heightened awareness of CD40L antibody benefits in organ transplantation, and the expansion of clinical trials for immunosuppressive applications. Major trends include advancements in antibody engineering, the development of bispecific antibodies for targeted therapies, innovations in delivery methods, progress in combination therapies, advancements in personalized medicine, and the development of biomarkers for improved patient selection.

The increasing prevalence of autoimmune disorders is expected to drive growth in the CD40 ligand (CD40L) antibody market. Autoimmune disorders arise when the immune system mistakenly attacks the body’s own cells, leading to conditions such as rheumatoid arthritis, lupus, and type 1 diabetes. The rising incidence of these disorders can be linked to factors including environmental triggers, genetic predisposition, lifestyle changes, and greater diagnostic awareness, all of which contribute to higher detection rates. CD40L antibodies are emerging as a promising therapeutic approach for managing autoimmune disorders by regulating the immune system’s overactive response. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency responsible for health and welfare statistics, reported that in 2022, approximately 514,000 Australians (2% of the population) were living with rheumatoid arthritis. The condition affected 2.5% of females and 1.6% of males. As a result, the rising incidence of autoimmune disorders is fueling the expansion of the CD40L antibody market.

Companies in the CD40L antibody market are advancing clinical trials and expanding therapeutic applications to enhance immune modulation. Clinical trials systematically assess the safety, efficacy, and optimal use of medical treatments. For example, in September 2023, Eledon Pharmaceuticals Inc., a US-based biotechnology company, announced the use of its anti-CD40L antibody, Tegoprubart, in a clinical trial following the second-ever genetically modified pig heart transplant. The trial aimed to evaluate its role in preventing organ rejection and expanding therapeutic applications in organ transplantation. Additionally, Tegoprubart has demonstrated potential in treating autoimmune diseases by modulating immune responses.

In January 2023, eGenesis Inc., a US-based biotechnology company, partnered with Eledon Pharmaceuticals Inc. Through this collaboration, eGenesis aims to integrate Eledon’s anti-CD40L antibody, Tegoprubart, into its preclinical research focused on developing human-compatible organs and cells for transplantation. Eledon Pharmaceuticals Inc. specializes in the development of novel immunotherapies, and this strategic partnership is expected to contribute to advancements in transplantation research and immunotherapy development.

Major players in the cd40 ligand (cd40l) antibody market are Thermo Fisher Scientific Co. Ltd., Amgen Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Kiniksa Pharmaceuticals Ltd., BioLegend, Cytek Biosciences Inc., Sino Biological Inc., ACROBiosystems, Elabscience Biotechnology Inc., Cayman Chemical, Eledon Pharmaceuticals, Cell Signaling Technology, Enzo Biochem, GeneTex, GeminiBio, Creative Biolabs, BPS Bioscience Inc., LSBio, MyBiosource Inc., Boster Biological Technology, Bio X Cell, Assay Genie, Abeomics, Leinco Technologies Inc.

North America was the largest region in the CD40 ligand (CD40L) antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in CD40 ligand (CD40L) antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the CD40 ligand (CD40L) antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

CD40 ligand (CD40L) antibody is a therapeutic agent that targets the CD40L protein to inhibit CD40-CD40L interactions, thereby modulating immune responses for use in autoimmune diseases, transplant rejection, and cancer immunotherapy. By blocking this interaction, CD40L antibodies play a crucial role in regulating immune activation.

The primary types of CD40L antibodies include monoclonal and polyclonal antibodies. Monoclonal antibodies are derived from a single cell clone and are specifically designed to target a particular epitope on an antigen. These antibodies are used in various applications, including flow cytometry, enzyme-linked immunosorbent assay (ELISA), western blotting, immunoprecipitation, and immunofluorescence. The key end users of CD40L antibodies include hospitals, research institutes, specialty clinics, and other medical and scientific institutions.

The cd40 ligand (cd40l) antibody market research report is one of a series of new reports that provides cd40 ligand (cd40l) antibody market statistics, including the cd40 ligand (cd40l) antibody industry's global market size, regional shares, competitors with a cd40 ligand (cd40l) antibody market share, detailed cd40 ligand (cd40l) antibody market segments, market trends and opportunities, and any further data you may need to thrive in the cd40 ligand (cd40l) antibody industry. This cd40 ligand (cd40l) antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The CD40 ligand (CD40L) antibody market consists of revenues earned by entities by providing services such as custom antibody development, recombinant antibody engineering, antibody purification, and functional assays and validation. The market value includes the value of related goods sold by the service provider or included within the service offering. The CD40 ligand (CD40L) antibody market includes sales of infusion pumps and monoclonal antibody testing systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.